Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,174 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Imaging Agent Clear all
Completed Phase 2 Interventional

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

NCT04010357
View directory record Official record
Conditions
Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions
Abemaciclib,
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting No phase listed Observational

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

NCT07139899
View directory record Official record
Conditions
Severe Asthma
Interventions
Hyperpolarized Xenon 129
Combination Product
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 21, 2026, 6:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry

NCT04661657
View directory record Official record
Conditions
Covid19, Cardiac Disease, Cardiac Arrhythmia, Myocarditis, Left Ventricular Dysfunction
Interventions
Transthoracic echocardiogram (TTE), Cardiovascular Magnetic Resonance (CMR) Imaging
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Early Phase 1 Interventional

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

NCT03154411
View directory record Official record
Conditions
Primary Soft-tissue Sarcoma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting Phase 1 Interventional

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

NCT07619599
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

NCT03556384
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Adam Burgoyne, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

NCT02440334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Optison
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 21, 2026, 6:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

NCT04340843
View directory record Official record
Conditions
Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
39
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00089024
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 21, 2026, 6:59 PM EDT
Suspended Phase 1 Interventional

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

NCT06888323
View directory record Official record
Conditions
Refractory Myelodysplastic Syndrome
Interventions
Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab, Computed Tomography, Single Photon Emission Computed Tomography
Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02148783
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 21, 2026, 6:59 PM EDT
Completed No phase listed Observational

Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

NCT00946140
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DCE-MRI scans
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 1 Interventional

NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

NCT01808417
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Near Infrared Imaging
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

NCT02142608
View directory record Official record
Conditions
Prostate Cancer
Interventions
BR55
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
50 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 21, 2026, 6:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417
View directory record Official record
Conditions
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Irvine, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 6:59 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608
View directory record Official record
Conditions
Healthy
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 6:59 PM EDT